Current Challenges in the Diagnosis and Treatment of Lung Cancer

Friday, September 29, 2017
Seattle
Faculty

COURSE DIRECTORS

Steven H. Kirtland, MD, FCCP
Chief of Staff; Medical Director, Cancer Institute
Pulmonary and Critical Care Medicine, Undersea and Hyperbaric Medicine
Virginia Mason, Seattle, Wash.

Michal (Misho) Hubka, MD
Thoracic Surgeon, Section of General Thoracic and Vascular Surgery
Virginia Mason, Seattle, Wash.

KEYNOTE SPEAKER

Frank C. Detterbeck, MD
Professor of Surgery; Chief, Thoracic Surgery; Director, Thoracic Oncology
Yale School of Medicine, New Haven, Conn.

GUEST FACULTY

David Ross Camidge, MD, PhD
Joyce Zeff Chair in Lung Cancer Research
Director, Thoracic Oncology, Division of Medical Oncology
University of Colorado Denver School of Medicine, Denver, Colo.

Joelle Fathi, DNP, RN, ARNP, ANP-BC, CTTS
Clinical Assistant Professor, University of Washington School of Nursing
Program Director, Tobacco Related Diseases and Lung Cancer Screening Program
Swedish Cancer Institute, Seattle, Wash.

Janet Freeman-Daily
Lung Cancer Patient/Activist
Seattle, Wash.

Lindy S. Klaff, MD
Pulmonologist
EvergreenHealth Pulmonary Care, Kirkland, Wash.

VIRGINIA MASON FACULTY

Kas Ray Radiozamani, MD
Section of Radiation Oncology
Floyd & Delores Jones Cancer Institute

Richard M. Hinke, MD
Radiology

Joseph Rosales, MD
Hematologist-Oncologist
Floyd & Delores Jones Cancer Institute

Guobin Song, MD, PhD
Section of Radiation Oncology
Floyd & Delores Jones Cancer Institute

Kristin Bohreer, RN
Pulmonary and Critical Care

Anthony J. Gerbino, MD
Section Head, Pulmonary Medicine

Donald G. Guinee, Jr., MD
Laboratory and Pathology
Floyd & Delores Jones Cancer Institute
This course will explore specific challenging issues in the diagnosis and treatment of lung cancer. The importance of appropriate lung cancer screening, staging and radiographic and invasive evaluation will be presented. Difficult therapeutic topics include the appropriate treatment of indolent cancers, radiation versus surgery for early stage disease, and the rapidly expanding role of targeted and immunotherapy. The importance of a multi-disciplinary evaluation — including the patient’s perspective — will be discussed. Finally, live diagnostic and surgical cases will be presented along with actual case reviews by a tumor board panel.

Teaching methods include lecture, question and answer with faculty, live case demonstration, case discussion, patient experience, and hands-on practice.

**TARGET AUDIENCE:**
This course is designed for physicians, fellows and residents in pulmonology, oncology, radiology, internal medicine and hospital medicine. This course will also be of interest to physician assistants, nurse practitioners, and mid-level providers with an interest in lung cancer.

**OBJECTIVES:**
At the conclusion of this activity, participants should be able to:

- Manage the challenges in setting up and maintaining a successful lung cancer screening program
- Discuss pragmatic approaches to address smoking cessation in a lung cancer screening program
- Apply the new Fleischner criteria and staging recommendations
- Discuss the potential of liquid biopsies and genetic analysis in the workup of the suspicious nodule
- Describe links between the histologic and radiologic features of various types of lung cancer and its mimics
- Summarize the benefits and risks of surgical and radiation therapy in early stage disease
- Review actionable molecular subtypes of advanced NSCLC
- Summarize recent data regarding use of PD-1/PD-L1 active agents
- Discuss value to patients of biomarker testing, targeted therapy and immunotherapy
- Cite the role of multi-disciplinary boards in patient care

**Credit Designation:** Virginia Mason Medical Center designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.75 MOC points in the American Board of Internal Medicine's...
Agenda

7:00 a.m.  Registration opens, breakfast selection available

7:30 a.m.  **Grand Rounds Presentation: Indolent Lung Cancer**  | Frank Detterbeck, MD

8:30 a.m.  Break

8:45 a.m.  **Introduction and Overview**  | Steven Kirtland, MD

8:55 a.m.  **Lung Cancer Screening: Triumphs and Pitfalls**  
Steven Kirtland, MD and Kristin Bohreer, RN

9:20 a.m.  **Integrating Appropriate Best Practices for Smoking Cessation into a Lung Cancer Screening Program**  | Joelle Fathi, ARNP

9:45 a.m.  **The Ever Changing Criteria: Review of the new Fleischner criteria and 8th edition staging recommendations**  | Lindy Klaff, MD

10:10 a.m.  Break

10:25 a.m.  **Pulmonary Nodule Workup and Staging**  
Frank Detterbeck, MD and Steven Kirtland, MD

10:50 a.m.  **Radio-Pathologic Correlation of Lung Cancer**  
Donald Guinee, MD and Richard Hinke, MD

11:15 a.m.  **Case Presentation and Panel Discussion: Diagnosis**  
*Panel:* Frank Detterbeck, MD; Tony Gerbino, MD; Donald Guinee, MD and Richard Hinke, MD

12:00 p.m.  Break for box lunch selection and reconvene in auditorium

12:15 p.m.  **Live Case Presentation: Electromagnetic Navigation (EMN) Marking and Limited Wedge Resection**

1:15 p.m.  **Debate: SBRT vs. Surgery for Primary Lung Cancer**  
Kas Ray Badiozamani, MD and Misho Hubka, MD

1:40 p.m.  Break

1:50 p.m.  **Targeted Therapy in NSCLC: Evolution, revolution and interface with chemo and immunotherapy**  | Ross Camidge, MD

2:35 p.m.  **Immunotherapy in Lung Cancer**  | Joseph Rosales, MD

3:00 p.m.  **The Importance of Patient Access to Novel Therapies and Online Resources**  | Janet Freeman-Daily

3:25 p.m.  **Case Presentation and Panel Discussion: Treatment**  
*Panel:* Kas Ray Badiozamani, MD; Ross Camidge, MD; Frank Detterbeck, MD; Donald Guinee, MD and Richard Hinke, MD

4:10 p.m.  **Final Questions, Closing Comments**

4:15 p.m.  Adjourn

(ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Location: The course will be held in Volney Richmond Auditorium on Level One of the Virginia Mason Lindeman Pavilion, 1201 Terry Avenue, Seattle (between Seneca & University Streets.) Please note the Terry Street entrance into Lindeman Pavilion is Level Two. For information, contact the CME Department at (206) 341-0142 or email cme@virginiamason.org.
REGISTRATION:
Current Challenges in the Diagnosis and Treatment of Lung Cancer
Friday, September 29, 2017

Please print clearly

NAME

DEGREE/CREDS

SPECIALTY

ORGANIZATION

ADDRESS

CITY/STATE/ZIP

PHONE

E-MAIL

Please provide one question for the faculty:

☐ I will attend at the Videoconferencing Site in: ________________________________
   For information, call (206) 341-0142.

☐ Please add me to your e-mail list for news of upcoming CME courses at Virginia Mason.

PAYMENT:

Tuition: $195.00

☐ Check enclosed. Make check payable to VMMC – CME

☐ Please charge my: ☐ VISA ☐ MasterCard ☐ American Express ☐ Discover

CARD NUMBER

EXPIRATION DATE

CARDHOLDER NAME

SIGNATURE

Cancellation and Refund Policy: Refunds will be made for a fee of $25 if written notice of cancellation is received at least 14 calendar days prior to the activity.